HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 216 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $698 | +5.8% | 18,281 | 0.0% | 0.04% | +15.2% |
| Q2 2023 | $660 | -11.9% | 18,281 | -6.8% | 0.03% | 0.0% |
| Q1 2023 | $749 | -41.2% | 19,607 | -12.5% | 0.03% | -45.9% |
| Q4 2022 | $1,274 | -99.9% | 22,397 | -0.2% | 0.06% | +41.9% |
| Q3 2022 | $888,000 | +0.9% | 22,433 | +12.2% | 0.04% | +13.2% |
| Q2 2022 | $880,000 | +10.3% | 19,992 | 0.0% | 0.04% | +22.6% |
| Q1 2022 | $798,000 | -0.9% | 19,992 | -0.1% | 0.03% | +24.0% |
| Q4 2021 | $805,000 | -6.9% | 20,010 | -5.8% | 0.02% | -10.7% |
| Q3 2021 | $865,000 | -13.7% | 21,246 | -3.6% | 0.03% | -15.2% |
| Q2 2021 | $1,002,000 | -80.5% | 22,044 | -82.1% | 0.03% | -81.8% |
| Q1 2021 | $5,128,000 | -4.7% | 123,004 | -2.4% | 0.18% | -1.1% |
| Q4 2020 | $5,383,000 | +14.8% | 126,004 | -29.4% | 0.18% | +18.8% |
| Q3 2020 | $4,690,000 | -5.2% | 178,490 | -3.2% | 0.15% | +14.1% |
| Q2 2020 | $4,945,000 | +53.0% | 184,419 | +2.6% | 0.14% | +39.2% |
| Q1 2020 | $3,232,000 | +4.4% | 179,683 | +2.8% | 0.10% | +36.6% |
| Q4 2019 | $3,097,000 | +181.3% | 174,714 | +146.1% | 0.07% | +184.0% |
| Q3 2019 | $1,101,000 | -10.9% | 70,998 | -1.4% | 0.02% | -10.7% |
| Q2 2019 | $1,236,000 | +5.6% | 71,998 | -0.8% | 0.03% | +16.7% |
| Q1 2019 | $1,170,000 | +2.6% | 72,598 | -6.9% | 0.02% | -4.0% |
| Q4 2018 | $1,140,000 | +31.2% | 77,961 | +63.0% | 0.02% | +66.7% |
| Q3 2018 | $869,000 | +4.6% | 47,840 | -2.7% | 0.02% | +7.1% |
| Q2 2018 | $831,000 | -16.3% | 49,173 | -3.0% | 0.01% | -17.6% |
| Q1 2018 | $993,000 | -2.4% | 50,686 | +1.0% | 0.02% | 0.0% |
| Q4 2017 | $1,017,000 | +29.2% | 50,186 | -45.0% | 0.02% | -26.1% |
| Q2 2016 | $787,000 | +5.2% | 91,204 | +15.4% | 0.02% | 0.0% |
| Q1 2016 | $748,000 | -43.1% | 79,004 | +4.2% | 0.02% | -37.8% |
| Q4 2015 | $1,314,000 | +112.6% | 75,830 | +64.9% | 0.04% | +94.7% |
| Q3 2015 | $618,000 | – | 45,991 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |